Alkeus Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Boston MA United States (2011)

Organization Overview

First Clinical Trial
2014
NCT02230228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Alkeus Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

alk-001 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Geographic Atrophy (Phase 3)

Macular Degeneration (Phase 3)

Retinal Dystrophies (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1